Advancing kidney care in Singapore to extend lives, expand possibilities for patients

Singapore’s rising prevalence of kidney disease highlights the crucial need for efficient solutions to empower patients and care teams.  

About 850 million people globally live with chronic kidney disease (CKD) and 4 million are undergoing dialysis. In Singapore, approximately 500,000 people are diagnosed with the condition, with around six new cases of kidney failure recorded each day and more than 9,000 patients currently undergoing dialysis, according to the National Kidney Foundation Singapore. These increasing numbers have ranked the country third in the world for diabetes-induced kidney failure.

Faced with this rising tide, healthcare leaders have turned to innovation and technology to meet the evolving needs of patients and care teams.

Vantive, formerly Baxter’s Kidney Care segment, is a new standalone healthcare company providing solutions that redefine how kidney care and other vital organ therapies are delivered.

Over 1 million patients across more than 100 countries are supported by Vantive through meaningful innovations in kidney care.

“Our mission is to extend lives and expand possibilities for patients and care teams around the world,” said Steven Flynn, President of Vantive Asia-Pacific region. “Our therapies, digital technologies and advanced services are designed to support patients at home and in the clinic, as well as the most vulnerable patients in an intensive care unit (ICU) setting.”

Trusted partner for efficient solutions

Vantive takes pride in its Sharesource Connectivity Platform, a digital solution that enables two-way remote patient management for those undergoing home dialysis. This technology, designed for patients on peritoneal dialysis (PD), allows care teams to remotely monitor treatment data, provide timely interventions, and improve patient outcomes.

The company collaborates with clinicians and policymakers to make home dialysis more accessible and economically sustainable—an initiative that aligns with the Singapore Ministry of Health’s promotion of PD as the preferred dialysis modality.

PD is a dialysis therapy performed by the patient in their own home and is seen as a preferable modality for its lower infrastructure and resource needs compared to hospital-based haemodialysis which typically requires patients to travel to a clinic three times a week for five hours of therapy performed by a nurse. Home-based PD also offers patients reduced transport costs, as well as greater convenience and independence. Vantive takes this a step further, preserving patient freedom and enhancing patient outcomes through its home-based automated peritoneal dialysis (APD) solution which is performed at night whilst the patient sleeps, allowing them to work during the day and maintain their lifestyle needs.

Vantive’s HomeChoice Claria APD System, integrated with Sharesource, has user-friendly features that help end-stage kidney disease manage their home PD therapy whilst keeping them connected with their healthcare providers.

“As the first two-way remote patient management platform for PD, Sharesource has supported more than 60 million home dialysis therapy sessions globally,” Flynn said, noting the solutions that bank on the company’s 70-year legacy in kidney care.

“We believe that better care is possible when clinicians have the right tools to intelligently manage, monitor and optimise therapy administration,” he added.

Furthermore, Vantive goes beyond products and platforms as it deeply invests in knowledge sharing and professional development. Regular partnerships with healthcare providers to deliver education, technical support, and proactive patient services ensure that clinicians are equipped with the latest tools and insights.

Singapore as a hub of innovation

Singapore has been a strategic manufacturing and innovation hub for Vantive. Its Woodlands facility produces over 37 million units of dialysis fluid every year, with exports now expanding to Australia and New Zealand.

This reinforces Singapore’s role as a medtech manufacturing leader, all whilst contributing to the local economy including a more than SG$450m addition to GDP and support for over 4,000 local jobs.

As Vantive begins a new era in vital organ therapies and builds on its legacy as a local manufacturer in Singapore, it continues bringing innovation to this critical manufacturing hub and reinforces its position as a multi-domestic company.

The road ahead for Vantive includes continuous innovation and deeper impact, with plans on investing in local R&D, expanding home dialysis options, and delivering solutions that prioritise both the patient and clinician experience.

Whether it’s through digital optimisation, manufacturing, or life-enhancing therapies, Vantive is poised to be a vital partner in Singapore’s fight against kidney disease. To know more about them, visit https://www.vantive.com/.